Diabetes Treatment (cont.)Medical Author:
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MDMelissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology. Medical Editor:
William C. Shiel Jr., MD, FACP, FACR
William C. Shiel Jr., MD, FACP, FACRDr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology. Medical Editor:
Jay W. Marks, MD
Jay W. Marks, MDJay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles. In this Article
DPP-IV inhibitorsGLP-1 in the body is broken down by an enzyme called DPP IV. Logically, you can either make a synthetic GLP-1 that is not broken down by this enzyme (for example, Byetta) OR you could try to stop the enzyme that breaks down the GLP-1 your body already makes. Hence, the new class of drugs called DPP IV inhibitors. They do just that, that is, they inhibit this enzyme from breaking down GLP-1. This allows GLP-1 already in the blood to circulate longer. There are a number of companies working on this class of drug. A few years ago, the FDA approved the first drug in this class made by Merck and called sitagliptin (Januvia). Januvia can be used in combination with certain other medications and must be dose adjusted in patients with poor kidney function. In August 2009, a second drug in this class was approved, made Bristol Myers Squibb and Astra Zeneca called saxagliptin and marketed as Onglyza. In 2011, another drug in this class, linagliptin, marketed as Tradjenta was approved. These drugs have essentially the same side effect profile as Byetta; however, they are in pill form. While Byetta has a significant weight loss profile, DPP-IV inhibitors so far have had no effect on weight. Combination medicationsGlyburide/metformin (Glucovance), rosiglitazone/metformin (Avandamet), glipizide/metformin (Metaglip), and pioglitazone/metformin (Actoplus met), and metformin/sitagliptin (Janumet) are are five relatively new combination pills that are on the market to treat diabetes.
The benefit to these combination drugs is that there are fewer pills to take, hopefully leading to better compliance. While they work well, I personally like to give patients individual medications until I know what doses are working, and then switch to a combination pill once the patient has been stable on the doses of individual medications for a period of time. Reviewed by William C. Shiel Jr., MD, FACP, FACR on 4/4/2013 Patient CommentsViewers share their comments
Diabetes - Diet
Question: Have you found diet, exercise, and medication effective to control your diabetes?
Diabetes Treatment - Effective Treatments
Question: Please describe what treatments have been effective for your diabetes.
Diabetes Treatment - Medications
Question: Please discuss the medications you take to manage your diabetes.
Diabetes Treatment - Insulin Pump
Question: Do you use an insulin pump to treat your diabetes? Please describe the pros and cons of this type of treatment.
Diabetes Treatment - Insulin Pens
Question: Describe how you use pre-filled insulin pens and the environment in which they are most convenient for you.
|
Get the latest health and medical information delivered direct to your inbox FREE!


